Get the latest news from world and India’s leading pharmaceutical companies Pharma Industry, pharmaceutical marketing, generic drugs, and Complete news for Pharmacy and Life Sciences professionals.

  • AstraZeneca has fulfilled the deal of the core respiratory business of Takeda Pharmaceutical Company Limited. The agreement, announced in December 2015.  Agreement includes the expansion of rights to roflumilast (marketed as Daliresp in the US and Daxas in other countries), the only approved oral PDE4 inhibitor for the treatment of chronic obstructive pulmonary disease. AstraZeneca marketed Daliresp in the US in the first quarter of 2015.

  • Boston Scientific get U.S. Food and Drug Administration (FDA) approval for two catheters that can be used with the Rhythmia™ Mapping System. The IntellaNav™ XP and the IntellaNav MiFi™ XP navigation-enabled ablation catheters were approved to treat Type I atrial flutter. These are the first magnetically-tracked catheters that Boston Scientific will offer to the U.S. market. Type I atrial flutter  is an abnormal rhythm of the upper chambers of the heart.

  • Perrigo announced that it has received U.S.FDA approval for the generic version of Valeant Pharmaceutical International, Inc.'s BenzaClin® Pump Topical Gel. BenzaClin® Pump Topical Gel (clindamycin phosphate 1% and benzoyl peroxide 5%) is indicated for the topical treatment of acne vulgaris.

  • Axsome Therapeutics, Inc. received from the U.S. Food and Drug Administration (FDA) Fast Track designation for AXS-02 for the treatment of the pain of knee osteoarthritis (OA) associated with bone marrow lesions (BMLs). There is currently no product approved specifically for this indication.

  • Inovio Pharmaceuticals, Inc. announced that it has closed the transaction to acquire all of BioJect Medical Technologies Inc.s assets, including pioneering needle-free jet injection technology, devices, and intellectual property, which it first announced in a definitive agreement on March 14, 2016. Inovio acquired BioJect for USD 4.3 million in Inovio common stock and USD 1.2 million in cash.

    Inovio is advancing multiple novel cancer and infectious disease immunotherapies and vaccines as well as delivery devices to optimally administer them. Since administration of Inovio’s products is a two-step process involving injection and electroporation delivery, it is also focused on enhancing ease and cost of administration to best serve clinical requirements. An integrated injection and electroporation device that eliminates needles and reduces disposable materials in an automated process would be a paradigm-changing step in vaccine administration in large populations.

    Inovio has been developing needle-free electroporation technology that works on the surface of the skin. BioJect’s needle-free jet injection technology uses high pressure gas or springs to propel liquid medicine into skin. Its devices have demonstrated favorable utility, safety, and tolerability attributes in animals and humans. Under a prior research agreement Inovio tested the two separate technologies together and generated compelling antigen expression and immune responses in animals. Inovio will now be combining the two technologies into one highly optimized integrated delivery device.

    << Pharma News

    Subscribe to PharmaTutor News Alerts by Email >>

  • Roche announced new results from 19 approved and investigational medicines will be presented during the American Society of Clinical Oncology (ASCO) Annual Meeting from 3rd – 7th June in Chicago, United States. More than 200 abstracts have been accepted across eight cancer types, including four “late breakers” and nearly 30 oral presentations.

  • 5 May 2016
    Why appetite loss during illness or diseases ?

    Loss of appetite during illness is a common and potentially debilitating phenomenon—in cancer patients, especially, it can even shorten lifespan. Researchers of the Scripps Research Institute (TSRI) have discovered how an immune system molecule hijacks a brain circuit and reduces appetite. Their discovery points to possible targets for treating loss of appetite and restoring a patient’s strength.

  • With an aim to augment the Government of India’s ‘Skill India’ flagship project and to create a robust and vibrant eco-system for quality skill development in the healthcare sector, PHD Chamber of Commerce and Industry (PHDCCI) and Public Health Foundation of India (PHFI) signed a 5 year memorandum of understanding for launching a joint program to organize capacity building initiatives in skilling healthcare professionals especially in the areas of chronic diseases and prevention of Non Communicable Diseases (NCDs).

    [adsense:336x280:8701650588]

Subscribe to Pharma News